Allovir Inc is a biotechnology business based in the US. Allovir Inc shares (ALVR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $11.47 – the same closing value as a week prior. Allovir Inc employs 6 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $11.47 |
|---|---|
| 52-week range | $7.96 - $24.15 |
| 50-day moving average | $9.73 |
| 200-day moving average | $14.55 |
| Wall St. target price | $1.20 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-11.73 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $11.47 from 2025-03-19
| 1 week (2025-05-13) | N/A |
|---|---|
| 1 month (2025-04-20) | N/A |
| 3 months (2025-02-24) | 12.45% |
| 6 months (2024-11-22) | 1,985.83% |
| 1 year (2024-05-24) | 1,415.19% |
|---|---|
| 2 years (2023-05-24) | -87.56% |
| 3 years (2022-05-24) | 89.47 |
| 5 years (2020-05-20) | N/A |
| Gross profit TTM | $165,000 |
|---|---|
| Return on assets TTM | -22.33% |
| Return on equity TTM | -45.37% |
| Profit margin | 0% |
| Book value | $22.60 |
| Market Capitalization | $49.5 million |
TTM: trailing 12 months
We're not expecting Allovir Inc to pay a dividend over the next 12 months.
Allovir Inc's shares were split on a 1:23 basis on 15 January 2025 . So if you had owned 23 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Allovir Inc shares – just the quantity. However, indirectly, the new 2200% higher share price could have impacted the market appetite for Allovir Inc shares which in turn could have impacted Allovir Inc's share price.
Over the last 12 months, Allovir Inc's shares have ranged in value from as little as $7.96 up to $24.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Allovir Inc's is 0.617. This would suggest that Allovir Inc's shares are less volatile than average (for this exchange).
Allovir, Inc. , a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019.
Direct indexing lets you replicate the performance of a specific index with potentially more tax efficiency. Learn how to get started here.
These are the stocks to buy when you don’t have much to spend.
A deep dive into the highlights and limitations of Frec.
It can help reduce taxes owed, but it’s not for beginners.
Compare pros, cons, research tools and reviews for these two trading platforms.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
Compare pros, cons, research tools and reviews for these two trading platforms.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
The ins and outs of bundling stocks with this accessible investing option.
A deep dive into the highlights and limitations of Robinhood.